Matches in SemOpenAlex for { <https://semopenalex.org/work/W867580> ?p ?o ?g. }
Showing items 1 to 75 of
75
with 100 items per page.
- W867580 endingPage "73" @default.
- W867580 startingPage "169" @default.
- W867580 abstract "High dose interleukin-2 therapy, administered in bolus, is considered to be a reasonable treatment option in a selected group of patients with metastatic malignant melanoma.To present our experience using this mode of therapy in 21 patients with metastatic melanoma.The 21 patients in our study group comprised 13 men and 8 women with a mean age of 46 years (range 29-63). Their metastatic disease was present in all extracranial sites, dermal and sub-dermal metastases being the most common (15 patients had at least one site, in addition to other locations of metastases). Patients with intracranial disease were excluded due to the poor effectivity of IL-2 at this site. Treatment comprised a course of 2 weeks of therapy with a 1 week rest interval between. Radiological and physical evaluation was performed 6-8 weeks after the first course. If a response was achieved a second course of therapy was given. Patients received up to 14 planned doses of IL-2 in each week, 720,000 IU/kg of IL-2 per dose i.v. in 15 minutes. All treatments were given in the surgical ward, and only one patient was hospitalized in the intensive care unit.Of the 21 patients, one had a complete response that has lasted for 17 months and 5 patients had a partial response (range 3 months to 3 years). One patient died during treatment, and one patient who refused further treatment because of no response died a few days after completion of treatment. Prior to therapy three of the responders had received autologous vaccines with good immunological response (P = 0.115). Toxic side effects were significant, but they were treated successfully with no residual damage.High dose IL-2 can be administered safely in a surgical department. The response rates achieved in this series justify the use of high dose IL-2 in a selected group of patients. To improve response rates, a combination of autologous vaccines prior to high dose IL-2 may be recommended." @default.
- W867580 created "2016-06-24" @default.
- W867580 creator A5020976042 @default.
- W867580 creator A5052396098 @default.
- W867580 creator A5074296844 @default.
- W867580 creator A5090003736 @default.
- W867580 date "2001-03-01" @default.
- W867580 modified "2023-10-18" @default.
- W867580 title "Bolus high dose interleukin-2 for the treatment of malignant melanoma." @default.
- W867580 cites W1480797220 @default.
- W867580 cites W1533133453 @default.
- W867580 cites W173244104 @default.
- W867580 cites W1884121283 @default.
- W867580 cites W1950572133 @default.
- W867580 cites W1981288213 @default.
- W867580 cites W1983806918 @default.
- W867580 cites W2002038445 @default.
- W867580 cites W200780746 @default.
- W867580 cites W2036840935 @default.
- W867580 cites W2067836768 @default.
- W867580 cites W2083357283 @default.
- W867580 cites W2089828715 @default.
- W867580 cites W2091850352 @default.
- W867580 cites W2130901389 @default.
- W867580 cites W2155906863 @default.
- W867580 cites W2167447755 @default.
- W867580 cites W2260176825 @default.
- W867580 cites W2322553446 @default.
- W867580 cites W2326245275 @default.
- W867580 cites W2344331512 @default.
- W867580 cites W2405336571 @default.
- W867580 cites W2411400845 @default.
- W867580 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11303372" @default.
- W867580 hasPublicationYear "2001" @default.
- W867580 type Work @default.
- W867580 sameAs 867580 @default.
- W867580 citedByCount "2" @default.
- W867580 crossrefType "journal-article" @default.
- W867580 hasAuthorship W867580A5020976042 @default.
- W867580 hasAuthorship W867580A5052396098 @default.
- W867580 hasAuthorship W867580A5074296844 @default.
- W867580 hasAuthorship W867580A5090003736 @default.
- W867580 hasConcept C141071460 @default.
- W867580 hasConcept C2777658100 @default.
- W867580 hasConcept C43376680 @default.
- W867580 hasConcept C502942594 @default.
- W867580 hasConcept C509974204 @default.
- W867580 hasConcept C71924100 @default.
- W867580 hasConceptScore W867580C141071460 @default.
- W867580 hasConceptScore W867580C2777658100 @default.
- W867580 hasConceptScore W867580C43376680 @default.
- W867580 hasConceptScore W867580C502942594 @default.
- W867580 hasConceptScore W867580C509974204 @default.
- W867580 hasConceptScore W867580C71924100 @default.
- W867580 hasIssue "3" @default.
- W867580 hasLocation W8675801 @default.
- W867580 hasOpenAccess W867580 @default.
- W867580 hasPrimaryLocation W8675801 @default.
- W867580 hasRelatedWork W2002120878 @default.
- W867580 hasRelatedWork W2003938723 @default.
- W867580 hasRelatedWork W2019517015 @default.
- W867580 hasRelatedWork W2047967234 @default.
- W867580 hasRelatedWork W2118496982 @default.
- W867580 hasRelatedWork W2364998975 @default.
- W867580 hasRelatedWork W2369162477 @default.
- W867580 hasRelatedWork W2439875401 @default.
- W867580 hasRelatedWork W2519357708 @default.
- W867580 hasRelatedWork W2525756941 @default.
- W867580 hasVolume "3" @default.
- W867580 isParatext "false" @default.
- W867580 isRetracted "false" @default.
- W867580 magId "867580" @default.
- W867580 workType "article" @default.